Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
ADAMTSL2 mutations determine the phenotypic severity in geleophysic dysplasia
Vladimir Camarena, Monique M. Williams, Alejo A. Morales, Mohammad F. Zafeer, Okan V. Kilic, Ali Kamiar, Clemer Abad, Monica A. Rasmussen, Laurence M. Briski, LéShon Peart, Guney Bademci, Deborah S. Barbouth, Sarah Smithson, Gaofeng Wang, Lina A. Shehadeh, Katherina Walz, Mustafa Tekin
Vladimir Camarena, Monique M. Williams, Alejo A. Morales, Mohammad F. Zafeer, Okan V. Kilic, Ali Kamiar, Clemer Abad, Monica A. Rasmussen, Laurence M. Briski, LéShon Peart, Guney Bademci, Deborah S. Barbouth, Sarah Smithson, Gaofeng Wang, Lina A. Shehadeh, Katherina Walz, Mustafa Tekin
View: Text | PDF
Resource and Technical Advance Genetics

ADAMTSL2 mutations determine the phenotypic severity in geleophysic dysplasia

  • Text
  • PDF
Abstract

Geleophysic dysplasia-1 (GD1) is an autosomal recessive disorder caused by ADAMTS-like 2 (ADAMTSL2) variants. It is characterized by distinctive facial features, limited joint mobility, short stature, brachydactyly, and life-threatening cardiorespiratory complications. The clinical spectrum spans from perinatal lethality to milder adult phenotypes. We developed and characterized cellular and mouse models, to replicate the genetic profile of a patient who is compound heterozygous for 2 ADAMTSL2 variants, namely p.R61H and p.A165T. The impairment of ADAMTSL2 secretion was observed in both variants, but p.A165T exhibited a more severe impact. Mice carrying different allelic combinations revealed a spectrum of phenotypic severity, from lethality in knockout homozygotes to mild growth impairment observed in adult p.R61H homozygotes. Homozygous and hemizygous p.A165T mice survived but displayed severe respiratory and cardiac dysfunction. The respiratory dysfunction mainly affected the expiration phase, and some of these animals had microscopic post-obstructive pneumonia. Echocardiograms and MRI studies revealed a significant systolic dysfunction, accompanied by a reduction of the aortic root size. Histology verified the presence of hypertrophic cardiomyopathy with myocyte hypertrophy, chondroid metaplasia, and mild interstitial fibrosis. This study revealed a substantial correlation between the degree of impaired ADAMTSL2 secretion and the severity of the observed phenotype in GD1.

Authors

Vladimir Camarena, Monique M. Williams, Alejo A. Morales, Mohammad F. Zafeer, Okan V. Kilic, Ali Kamiar, Clemer Abad, Monica A. Rasmussen, Laurence M. Briski, LéShon Peart, Guney Bademci, Deborah S. Barbouth, Sarah Smithson, Gaofeng Wang, Lina A. Shehadeh, Katherina Walz, Mustafa Tekin

×

Figure 1

Mutant ADAMTSL2 secretion is impaired, and p.A165T causes a more severe impairment than p.R61H.

Options: View larger image (or click on image) Download as PowerPoint
Mutant ADAMTSL2 secretion is impaired, and p.A165T causes a more severe ...
(A) ADAMTSL2 is detected in cell lysates and the conditioned media (CM) of HEK293T cells at 24–48 hours after transfection with p.R61H, p.A165T, or wild-type (WT) ADAMTSL2-DDK. (B) Densitometry analysis of the CM/cells ratio shows a reduction of ADAMTSL2-DDK in the extracellular space when it is mutated. (C) Secretion of ADAMTSL2 in the CM is further reduced when 2 mutations are cotransfected in HEK293T cells 48 hours after transfection. (D) Densitometry analysis of the CM/cells ratio shows a further reduction of ADAMTSL2-DDK in the extracellular space when 2 mutants are cotransfected. (E) ADAMTSL2 is detected in the CM of HEK293T cells 48 hours after transfection with p.R61H-ADAMTSL2-DDK cotransfected with increased doses of either p.R61H- or p.A165T-ADAMTSL2-His. (F) Densitometry analysis of the CM/cells ratio shows a further reduction of p.R61HADAMTSL2-DDK in the extracellular space when cotransfected with p.A165T-ADAMTSL2-His. (G) ADAMTSL2 secretion is impaired in GD1 fibroblasts. Red arrows show ADAMTSL2 in the total lysate and intracellular and extracellular compartment. Glycosylation and fucosylation of ADAMTSL2 likely cause the higher molecular weight bands detected in the ECM. GAPDH and fibronectin were used as cytoplasmic and ECM markers, respectively. (H) Densitometry analysis of the ADAMTSL2/GAPDH ratio shows a significant reduction of secreted ADAMTSL2 in the extracellular space of GD1 dermal fibroblasts compared with human dermal control fibroblasts. (A–H) The ECM/intracellular (IC) ratio was normalized with the intensity of the CM from WT sample 48 hours after transfection. Data shown as mean ± SEM. (*, P < 0.05; ***, P < 0.001, 2-tailed t test.) All densitometry analyses were done with at least 3 independent experiments.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts